Abstract
The dopamine D2 receptor is the main dopamine receptor expressed in the human normal pituitary gland. The aim of the current study was to evaluate dopamine D2 receptor expression in the corticotroph cell populations of the anterior lobe and pars intermedia, as well as posterior lobe of the human normal pituitary gland by immunohistochemistry. Human normal pituitary gland samples obtained from routine autopsies were used for the study. In all cases, histology together with immunostaining for adrenocorticotropic hormone, melanocyte-stimulating hormone, prolactin, and neurofilaments were performed and compared to the immunostaining for D2 receptor. D2 receptor was heterogeneously expressed in the majority of the cell populations of the anterior and posterior lobe as well as in the area localized between the anterior and posterior lobe, and arbitrary defined as “intermediate zone”. This zone, characterized by the presence of nerve fibers included the residual pars intermedia represented by the colloid-filled cysts lined by the remnant melanotroph cells strongly expressing D2 receptors, and clusters of corticotroph cells, belonging to the anterior lobe but localized within the cysts and adjacent to the posterior lobe, variably expressing D2 receptors. D2 dopamine receptor is expressed in the majority of the cell populations of the human normal pituitary gland, and particularly, in the different corticotroph cell populations localized in the anterior lobe and the intermediate zone of the pituitary gland.
Similar content being viewed by others
References
N. Ben-Jonathan, Dopamine: A prolactin-inhibiting hormone. Endocr. Rev. 6(4), 564–589 (1985). doi:10.1210/edrv-6-4-564
R. Pivonello, D. Ferone, G. Lombardi, A. Colao, S.W. Lamberts, L.J. Hofland, Novel insights in dopamine receptor physiology. Eur. J. Endocrinol. 156(Suppl 1), S13–S21 (2007). doi:10.1530/eje.1.02353
M.G. Caron, M. Beaulieu, V. Raymond, B. Gagne, J. Drouin, R.J. Lefkowitz, F. Labrie, Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J. Biol. Chem. 253(7), 2244–2253 (1978)
M. Munemura, T.E. Cote, K. Tsuruta, R.L. Eskay, J.W. Kebabian, The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization. Endocrinology 107(6), 1676–1683 (1980). doi:10.1210/endo-107-6-1676
S.W. Lamberts, R.M. Macleod, Regulation of prolactin secretion at the level of the lactotroph. Physiol. Rev. 70(2), 279–318 (1990)
J. Stack, A. Surprenant, Dopamine actions on calcium currents, potassium currents and hormone release in rat melanotrophs. J. Physiol. 439, 37–58 (1991)
M. Boschetti, F. Gatto, M. Arvigo, D. Esposito, A. Rebora, M. Talco, M. Albertelli, E. Nazzari, U. Goglia, F. Minuto, D. Ferone, Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology 92(Suppl 1), 17–22 (2010). doi:10.1159/000314293
P.C. Goldsmith, M.J. Cronin, R.I. Weiner, Dopamine receptor sites in the anterior pituitary. J. Histochem Cytochem 27(8), 1205–1207 (1979)
U. Renner, T. Arzberger, U. Pagotto, S. Leimgruber, E. Uhl, A. Muller, M. Lange, A. Weindl, G.K. Stalla, Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab. 83(4), 1368–1375 (1998). doi:10.1210/jcem.83.4.4685
L.V. Neto, O. Machado Ede, R.M. Luque, G.F. Taboada, J.B. Marcondes, L.M. Chimelli, L.P. Quintella, P. Niemeyer Jr., D.P. de Carvalho, R.D. Kineman, M.R. Gadelha, Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J. Clin. Endocrinol. Metab. 94(6), 1931–1937 (2009). doi:10.1210/jc.2008-1826
L. Stefaneanu, K. Kovacs, E. Horvath, M. Buchfelder, R. Fahlbusch, L. Lancranjan, Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14(3), 329–336 (2001)
Y. Wang, J. Li, M. Tohti, Y. Hu, S. Wang, W. Li, Z. Lu, C. Ma, The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. J. Exp. Clin. Cancer Res. 33, 56 (2014). doi:10.1186/s13046-014-0056-y
A. Saveanu, P. Jaquet, T. Brue, A. Barlier, Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol. Cell. Endocrinol. 286(1-2), 206–213 (2008). doi:10.1016/j.mce.2007.12.008
R. Pivonello, D. Ferone, W.W. de Herder, J.M. Kros, M.L. De Caro, M. Arvigo, L. Annunziato, G. Lombardi, A. Colao, L.J. Hofland, S.W. Lamberts, Dopamine receptor expression and function in corticotroph pituitary tumors. J. Clin. Endocrinol. Metab. 89(5), 2452–2462 (2004). doi:10.1210/jc.2003-030837
L. Vieira Neto, L.E. Wildemberg, A.B. Moraes, L.M. Colli, L. Kasuki, N.V. Marques, E.L. Gasparetto, M. de Castro, C.M. Takiya, M.R. Gadelha, Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin. Endocrinol. 82(5), 739–746 (2015). doi:10.1111/cen.12684
D. Bression, A.M. Brandi, A. Nousbaum, M. Le Dafniet, J. Racadot, F. Peillon, Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system. J. Clin. Endocrinol. Metab. 55(3), 589–593 (1982). doi:10.1210/jcem-55-3-589
F. Gatto, F. Barbieri, M. Gatti, R. Wurth, S. Schulz, J.L. Ravetti, G. Zona, M.D. Culler, A. Saveanu, M. Giusti, F. Minuto, L.J. Hofland, D. Ferone, T. Florio, Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. Clin. Endocrinol. 76(3), 407–414 (2012). doi:10.1111/j.1365-2265.2011.04200.x
R. van der Pas, R.A. Feelders, F. Gatto, C. de Bruin, A.M. Pereira, P.M. van Koetsveld, D.M. Sprij-Mooij, A.M. Waaijers, F. Dogan, S. Schulz, J.M. Kros, S.W. Lamberts, L.J. Hofland, Preoperative normalization of cortisol levels in Cushing’s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. J. Clin. Endocrinol. Metab. 98(12), E1880–E1890 (2013). doi:10.1210/jc.2013-1987
A.P. Amar, M.H. Weiss, Pituitary anatomy and physiology. Neurosurg. Clin. N. Am. 14(1), 11–23 (2003)
S.L. Asa, K. Kovacs, Functional morphology of the human fetal pituitary. Pathol. Annu. 19(Pt 1), 275–315 (1984)
I. Doniach, Histopathology of the pituitary. Clin. Endocrinol. Metab. 14(4), 765–789 (1985)
L.C. Saland, The mammalian pituitary intermediate lobe: an update on innervation and regulation. Brain. Res. Bull. 54(6), 587–593 (2001)
R.E. Mains, B.A. Eipper, Synthesis and secretion of corticotropins, melanotropins, and endorphins by rat intermediate pituitary cells. J. Biol. Chem. 254(16), 7885–7894 (1979)
D.I. Lugo, J.E. Pintar, Ontogeny of basal and regulated secretion from POMC cells of the developing anterior lobe of the rat pituitary gland. Dev. Biol. 173(1), 95–109 (1996). doi:10.1006/dbio.1996.0009
H. Shiomi, S.J. Watson, J.E. Kelsey, H. Akil, Pretranslational and posttranslational mechanisms for regulating beta-endorphin-adrenocorticotropin of the anterior pituitary lobe. Endocrinology 119(4), 1793–1799 (1986). doi:10.1210/endo-119-4-1793
P.A. Rosa, P. Policastro, E. Herbert, A cellular basis for the differences in regulation of synthesis and secretion of ACTH/endorphin peptides in anterior and intermediate lobes of the pituitary. J. Exp. Biol. 89, 215–237 (1980)
T. Murakami, A. Ohtsuka, T. Taguchi, A. Kikuta, O. Ohtani, Blood vascular bed of the rat pituitary intermediate lobe, with special reference to its development and portal drainage into the anterior lobe. A scanning electron microscope study of vascular casts. Archivum histologicum Japonicum = Nihon soshikigaku kiroku 48(1), 69–87 (1985)
J.L. Goudreau, S.E. Lindley, K.J. Lookingland, K.E. Moore, Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary. Neuroendocrinology 56(1), 100–105 (1992)
J.M. Saavedra, Central and peripheral catecholamine innervation of the rat intermediate and posterior pituitary lobes. Neuroendocrinology 40(4), 281–284 (1985)
M. Holzbauer, K. Racke, The dopaminergic innervation of the intermediate lobe and of the neural lobe of the pituitary gland. Med. Biol. 63(3), 97–116 (1985)
S.L. Lightman, M. Ninkovic, S.P. Hunt, Localization of [3H]spiperone binding sites in the intermediate lobe of the rat pituitary gland. Neurosci. Lett. 32(2), 99–102 (1982)
L. Desrues, M. Lamacz, B.G. Jenks, H. Vaudry, M.C. Tonon, Effect of dopamine on adenylate cyclase activity, polyphosphoinositide metabolism and cytosolic calcium concentrations in frog pituitary melanotrophs. J. Endocrinol. 136(3), 421–429 (1993)
H. Zhang, B.G. Jenks, A. Ciccarelli, E.W. Roubos, W.J. Scheenen, Dopamine D2-receptor activation differentially inhibits N- and R-type Ca2+ channels in Xenopus melanotrope cells. Neuroendocrinology 80(6), 368–378 (2004). doi:10.1159/000084144
D. Radl, C. De Mei, E. Chen, H. Lee, E. Borrelli, Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia. Mol. endocrinol. 27(6), 953–965 (2013). doi:10.1210/me.2013-1008
M.J. Cronin, M.O. Thorner, P. Hellmann, A.D. Rogol, Bromocriptine inhibits growth hormone release from rat pituitary cells in primary culture. Proc. Soc. Exp. Biol. Med. 175(2), 191–195 (1984)
S.M. Foord, J.R. Peters, C. Dieguez, M.F. Scanlon, R. Hall, Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin. Endocrinology 112(5), 1567–1577 (1983). doi:10.1210/endo-112-5-1567
D. Bression, A.M. Brandi, M.P. Martres, A. Nousbaum, F. Cesselin, J. Racadot, F. Peillon, Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. J. Clin. Endocrinol. Metab. 51(5), 1037–1044 (1980). doi:10.1210/jcem-51-5-1037
A. Colao, A. di Sarno, R. Pivonello, C. di Somma, G. Lombardi, Dopamine receptor agonists for treating prolactinomas. Expert. Opin. Investig. Drugs. 11(6), 787–800 (2002). doi:10.1517/13543784.11.6.787
A. Colao, D. Ferone, P. Marzullo, A. Di Sarno, G. Cerbone, F. Sarnacchiaro, S. Cirillo, B. Merola, G. Lombardi, Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82(2), 518–523 (1997). doi:10.1210/jcem.82.2.3648
R. Pivonello, C. Matrone, M. Filippella, L.M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, G. Lombardi, Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J. Clin. Endocrinol. Metab. 89(4), 1674–1683 (2004). doi:10.1210/jc.2003-030859
R. Pivonello, M.C. De Martino, P. Cappabianca, M. De Leo, A. Faggiano, G. Lombardi, L.J. Hofland, S.W. Lamberts, A. Colao, The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94(1), 223–230 (2009). doi:10.1210/jc.2008-1533
D. Ferone, C. Pivonello, G. Vitale, M.C. Zatelli, A. Colao, R. Pivonello, Molecular basis of pharmacological therapy in Cushing’s disease. Endocrine 46(2), 181–198 (2014). doi:10.1007/s12020-013-0098-5
F. Facchinetti, S. Bernasconi, L. Iughetti, A.D. Genazzani, L. Ghizzoni, A.R. Genazzani, Changes in dopaminergic control of circulating melanocyte-stimulating hormone-related peptides at puberty. Pediatr. Res. 38(1), 91–94 (1995). doi:10.1203/00006450-199507000-00016
A.B. Abou Samra, M. Pugeat, H. Dechaud, L. Nachury, J. Tourniaire, Acute dopaminergic blockade by sulpiride stimulates beta-endorphin secretion in pregnant women. Clin. Endocrinol. 21(5), 583–588 (1984)
J.R. Lundblad, J.L. Roberts, Regulation of proopiomelanocortin gene expression in pituitary. Endocr. Rev. 9(1), 135–158 (1988). doi:10.1210/edrv-9-1-135
M.M. Murburg, C.W. Wilkinson, M.A. Raskind, R.C. Veith, D.M. Dorsa, Evidence for two differentially regulated populations of peripheral beta-endorphin-releasing cells in humans. J. Clin. Endocrinol. Metab. 77(4), 1033–1040 (1993). doi:10.1210/jcem.77.4.8408451
J.M. Farah Jr., D. Sapun-Malcolm, G.P. Mueller, Apomorphine selectively stimulates opiocortin hormone release from the pars distalis in rats. Eur. J. Pharmacol. 107(3), 385–388 (1985)
J.H. Meador-Woodruff, B. Pellerito, D. Bronstein, H.L. Lin, N. Ling, H. Akil, Differential effects of haloperidol on the rat pituitary: decreased biosynthesis, processing and release of anterior lobe pro-opiomelanocortin. Neuroendocrinology 51(3), 294–303 (1990)
D. Jezova, M. Vigas, Apomorphine injection stimulates beta-endorphin, adrenocorticotropin, and cortisol release in healthy man. Psychoneuroendocrinology 13(6), 479–485 (1988)
M.M. Murburg, D. Paly, C.W. Wilkinson, R.C. Veith, K.L. Malas, D.M. Dorsa, Haloperidol increases plasma beta endorphin-like immunoreactivity and cortisol in normal human males. Life. Sci. 39(4), 373–381 (1986)
S. Kuebber, S. Ropte, A. Hori, Proliferation of adenohypophyseal cells into posterior lobe. Their normal anatomical condition and possible neoplastic potentiality. Acta Neurochir. 104(1-2), 21–26 (1990)
X. Fan, S.J. Olson, M.D. Johnson, Immunohistochemical localization and comparison of carboxypeptidases D, E, and Z, alpha-MSH, ACTH, and MIB-1 between human anterior and corticotroph cell “basophil invasion” of the posterior pituitary. J. Histochem. Cytochem. 49(6), 783–790 (2001)
A. Godbout, M. Manavela, K. Danilowicz, H. Beauregard, O.D. Bruno, A. Lacroix, Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur. J. Endocrinol. 163(5), 709–716 (2010). doi:10.1530/EJE-10-0382
R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The Treatment of Cushing’s Disease. Endocr. Rev. 36(4), 385–486 (2015). doi:10.1210/er.2013-1048
R. Pivonello, M.C. De Martino, M. De Leo, G. Lombardi, A. Colao, Cushing’s Syndrome. Endocrinol. Metab. Clin. N. Am. 37(1), 135–149 (2008). doi:10.1016/j.ecl.2007.10.010
L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, S. Endocrine, Treatment of Cushing’s Syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 100(8), 2807–2831 (2015). doi:10.1210/jc.2015-1818
R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M.K.A.C. Biller: Complications of cushing’s syndrome: State of the art. Lancet Diabetes Endocrinol. (In press 2016)
D. Vassiliadi, S. Tsagarakis, Unusual causes of Cushing’s syndrome. Arq. Bras. Endocrinol. Metabol. 51(8), 1245–1252 (2007)
Acknowledgements
We are greatly indebted to Professor Uberto Pagotto, Professor Philippe Chanson and Professor Sylvia Asa for the revision of the manuscript and the crucial suggestions, which improved the quality of the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Rights and permissions
About this article
Cite this article
Pivonello, R., Waaijers, M., Kros, J.M. et al. Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. Endocrine 57, 314–325 (2017). https://doi.org/10.1007/s12020-016-1107-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1107-2